YD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES. The filing lists him as a director and indicates no reported purchases, sales, or other insider transactions, with all transaction counts and share totals recorded as zero.
YD Bio Ltd executive Zhang Bo-Xiang, the Chief Medical Officer, has filed an initial ownership report showing direct holdings of 31,141 Ordinary Shares. This Form 3 does not reflect a new buy or sell transaction; it simply establishes his current stake as a company insider.
YD Bio Ltd executive Hen Man Edmund, the Chief Financial Officer, filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company but does not report any purchases, sales, or other equity transactions.
YD Bio Ltd CEO Dr. Ethan Shen filed an initial ownership report showing 11,224,153 Ordinary Shares held directly and 43,120,858 held indirectly. The indirect holdings are owned through YD Biopharma Holding Limited and E820N Assets Ltd., which are ultimately controlled by The E820N Trust where Dr. Shen is settlor, protector and sole beneficiary.
YD Bio Limited files a Prospectus Supplement registering 11,500,000 ordinary shares issuable upon exercise of public warrants, alongside disclosures for 59,136,934 ordinary shares by selling shareholders and 5,425,000 ordinary shares issuable upon exercise of warrants, to the Prospectus dated November 17, 2025.
The supplement incorporates a Form 6-K reporting that subsidiary YD Bio USA, Inc. entered a Master Strategic Alliance Agreement with YC Biotech Co., Ltd. on February 24, 2026
The filing also notes a reported last sale price of $8.42 per share on February 25, 2026 and attaches a press release describing the parties’ plan to build a "Taiwan-U.S. Dual-Core" regulatory platform with YD Bio USA as exclusive U.S. Agent for FDA-related submissions.
YD Bio Limited announced that its U.S. subsidiary, YD Bio USA, has entered a Master Strategic Alliance Agreement with YC Biotech to build a Taiwan-U.S. “Dual-Core” regulatory platform. YD Bio USA becomes YC Biotech’s exclusive U.S. Agent and formal liaison to the FDA for its Asian CRO clients.
The partnership covers a wide range of FDA interactions, including IND, NDA, BLA, IDE, 510(k), De Novo, and PMA submissions, as well as inspection readiness and ongoing regulatory strategy. YC Biotech will lead project acquisition and technical execution, while YD Bio USA handles U.S. regulatory interface and strategy.
The company describes this as a shift from single-project advisory work toward a scalable platform designed to onboard more Asian CRO partners, potentially expand to EMA-related work, and deepen a U.S. clinical network. Management notes that its pipeline already includes projects that have completed INTERACT, pre-IND, and IND meetings.
YD Bio Ltd files an amended Schedule 13G showing beneficial ownership stakes. The filing reports that Ethan Shen beneficially owns 54,345,011 ordinary shares (77.06%) and YD Biopharma Holding Limited beneficially owns 43,120,858 ordinary shares (61.15%). The filing states these percentages are calculated from a total of 70,521,359 ordinary shares as of November 17, 2025, per the issuer's Rule 424(b)(3) prospectus. The cover-page rows break ownership into sole and shared voting and dispositive powers, with Mr. Shen holding 11,224,153 sole voting and dispositive shares and 43,120,858 shared voting and dispositive shares through the Cayman Islands entity.
YD Bio Limited filed a prospectus supplement tied to its Form F-1, covering 11,500,000 ordinary shares issuable on exercise of public warrants, 59,136,934 ordinary shares offered by selling shareholders, and 5,425,000 ordinary shares issuable upon exercise of additional warrants. The supplement attaches a Form 6-K describing a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology (SSMC) through a new holding company for total consideration of NT$839,832,000 (approximately US$26.87 million) paid in a mix of cash and newly issued YD Bio shares. Large SSMC shareholders will receive YD Bio shares via share swap, while others can choose cash or shares, all subject to six‑month or one‑year lock‑ups. Closing depends on due diligence, SSMC’s restructuring and no material adverse change, with diligence targeted by March 20, 2026 and closing about 30 days later, after which YD Bio would indirectly own all of SSMC’s business and assets.
YD Bio Limited has entered into a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. (“SSMC”), a Taiwan-based dendritic cell immunotherapy platform. The deal is structured through a new offshore holding entity, Safe Save Cell (KY) Holdings Limited, which will hold 100% of SSMC’s equity.
The total consideration is expected to be NT$839,832,000 (approximately US$26.87 million), paid in a mix of cash and newly issued YD Bio ordinary shares. Large SSMC shareholders, including the founder and affiliates, will receive YD Bio shares via share swap, while other shareholders may choose cash or shares. New shares will be locked up for six months for general shareholders and one year for specific shareholders.
Closing is subject to due diligence, SSMC’s restructuring, and no material adverse change, with due diligence targeted by March 20, 2026 and closing expected within 30 days thereafter. After completion, YD Bio expects to own all of SSMC’s shares, business, and assets, strengthening its position in advanced immunocell and cancer therapies.
YD Bio Limited reports governance changes and a listing status update. On January 16, 2026, the Board appointed Dr. Chang as Chairman of the Compensation Committee and as a member of the Audit Committee and the Nominating and Corporate Governance Committee. On the same date, Dr. Lu was appointed Chairman of the Nominating and Corporate Governance Committee and as a member of the Audit Committee and Compensation Committee.
The company states that Dr. Chang and Dr. Lu have no material related-party interests, arrangements, or family relationships requiring disclosure under specified SEC regulations. On January 20, 2026, YD Bio notified Nasdaq that it has regained compliance with Audit Committee requirements under Nasdaq Listing Rule 5605 and is no longer in a cure period under Listing Rule 5605(c)(4)(B).